Immundiagnostik

Part of the Handbuch der inneren Medizin book series (INNEREN, volume 4 / 4 / A)

Zusammenfassung

Die Immundiagnostik maligner Tumoren orientiert sieh an der Serodiagnostik immunogener Infektionskrankheiten. Diese erlaubt die ätiopathogenetische Diagnose in einem frühen Krankheitsstadium und unabhängig vom klinischen Erscheinungsbild, sogar bei subklinischer Erkrankung. Obwohl die Ätiologie maligner Tumoren vielfältig ist, finden sich immunologisch malignitätstypische Veränderungen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Boelsma E, Rumke P (EDS) (1979) Tumor markers; impact and prospects. int workshop vom oktober 1978 in lunteren. Elsevier, north holland pressGoogle Scholar
  2. Colnaghi MI, Buraggi GL, Ghione M (eds) (1982) markers for diagnosis and monitoring of human cancer symposion vom april 1981 in Mailand. In: proc of the sereno symposia, vol 46. Academic press, new yorkGoogle Scholar
  3. Herberman RB, Mclntire KR (eds) (1979) Immunodiagnosis of cancer. Dekker, new yorkGoogle Scholar
  4. Nieburgs HE, Birkmayer GD, Klavins JV (eds) (1983) human tumor markers. Biological basis and clinical relevance 1. Int conf on human tumor markers vom juni 1982 in münchen. Alan R Liss, New YorkGoogle Scholar
  5. Primack A (1974) the production of markers by bronchigenic carcinoma, A Review. Semin Oncol 1:235–244Google Scholar
  6. Richardson RL, Greco FA, Oldham RK, Liddle GW (1978) tumor products and potential markers In small cell lung crarcinoma. Semin Oncol 5:253–262Google Scholar
  7. Uhlenbrock G, Wintzer RG (eds) (1981) Cea und andere tumormarker. Int symp vom oktober 1980 in köln. Tumor-diagnostik-verlag, leonbergGoogle Scholar
  8. Ziegenbein R (1982) Tumor-Marker; neue aspekte für die labordiagnostik. Fischer, StuttgartGoogle Scholar
  9. Abderhalden E (1941) Abwehrfermente (Die Abderhaldensche Reaktion). Steinkopf, Dresden LeipzigGoogle Scholar
  10. Ascoli M (1901) Isogglutinine und Isolysine menschlicher Blutsera. Muench Med Wochenschr 47: 1239–1241Google Scholar
  11. Ascoli M (1935) Störung des Lipidhaushaltes bei malignen Tumoren. Klin Wochenschr 14: 1593–1597CrossRefGoogle Scholar
  12. Atkinson RJ, Lowry WS, Strain P (1983) An analysis of the SCM test in cancer diagnosis. Cancer 52: 91–100PubMedCrossRefGoogle Scholar
  13. Bauer HW (1981) The pregnancy associated alpha-2-glycoprotein (a-2-PAG) - A tumormarker? Klin Wochenschr 59: 149–155PubMedCrossRefGoogle Scholar
  14. Bauer HW, Gropp C, Bohn H (1978) Schwangerschaftsassoziertes alpha-2-Glykoprotein im Serum von Patienten mit Bronchialkarzinom. Prax Pneumol 32: 194Google Scholar
  15. Baylin SB, Weisburger WR, Eggleston JC, Mendelsohn G, Beaven MA, Abeloff MD, Ettinger DS (1978) Variable content of histaminase, L-DOPA-decarboxylase and calcitonin in small cell carcinoma of the lung. N Engl J Med 299: 105–110PubMedCrossRefGoogle Scholar
  16. Bell CE, Seetharam S (1976) A plasma membrane antigen highly associated with oat-cell carcinoma of the lung and undetectable in normal adult tissue. Int J Cancer 18: 605–611PubMedCrossRefGoogle Scholar
  17. Björklund B (1980) On the nature and clinical use of the tissue polypeptide antigen (TPA). Tumor Diagnostik 1: 9–20Google Scholar
  18. Björklund B, Björklund V (1957) Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique; Presence of an insoluble, heatable tumor antigen. Int Arch Allergy 10: 153–184PubMedCrossRefGoogle Scholar
  19. Blackman MR, Kouridis IA, Rosen SW, Weintraub BD (1978) Comparative utility of human placental and pituitary glycoprotein hormones and subunits as tumor markers. Clin Res 26: 303AGoogle Scholar
  20. Bohn H (1972) Charakterisierung der schwangerschaftsassoziierten Glykoproteine als akute Phasen Proteine. Arch Gynekol 213: 54–72CrossRefGoogle Scholar
  21. Bondy PK, Gilby ED (1982) Endocrine function in small cell indifferentiated carcinoma of the lung. Cancer 50: 2147–2153PubMedCrossRefGoogle Scholar
  22. Braatz JA, Mclntire KR, Princler GL, Kortright KH, Herberman RB (1978) Purification and characterisation of a human lung tumor associated antigen. J Natl Cancer Inst 61: 1035–1046PubMedGoogle Scholar
  23. Braatz JA, Scharfe TR, Princler GL, Mclntire KR (1982) Characterisation of a human lung tumor associated antigen and development of a radioimmunoassay. Cancer Res 42: 849–855PubMedGoogle Scholar
  24. Braunstein GD, Forsythe AB, Rasor IL, Van Scoy Mosher MB, Thomson RW, Wade ME (1979) Serum glycoprotein hormone alpha-subunit levels in patients with cancer. Cancer 44: 1644–1657PubMedCrossRefGoogle Scholar
  25. Buffe D (1973) Fetoproteins and children tumors. Gann Monogr Cancer Res 14: 117–128Google Scholar
  26. Buffe D, Rimbaut C, Burtin P (1968) Presence d’une proteine d’origine tissulaire, l’alpha-H-globuline dans le serum de sujets atteints d’affections malignes. Int J Cancer 3: 850–856PubMedCrossRefGoogle Scholar
  27. Canal P, Bugat R, Soulagg, Combes PF (1981) Determination de la ß-HCG circulante ectopique dans les tumeurs solides. Pathol Biol (Paris) 29: 150–154Google Scholar
  28. Caspary EA, Field EJ (1971) Specific lymphocyte sensititation in cancer; Is there a common antigen in human malignant neoplasia? Br Med J 11: 612–617Google Scholar
  29. Cercek L, Cercek B (1977) Application of the phenomenon of changes in the structuredness of cytoplasmatic matrix (SCM) in the diagnosis of malignant disorders. A review. Eur J Cancer 13: 903–915PubMedCrossRefGoogle Scholar
  30. Coolen RB, Pragay DA, Nosanchuk JS, Beiding R (1979) Elevation of brain-type creatinine kinase in serum from patients with carcinoma. Cancer 44: 1414–1418PubMedCrossRefGoogle Scholar
  31. Dent PB, Louis JA, McCulloch PB, Dunnett CN, Cerottini JC (1979) Application of tumor marker analysis to patients with lung cancer. Schweiz Med Wochenschr 109: 827–830PubMedGoogle Scholar
  32. Douwes FR, Hüttermann, Mross K (1977) Immundiagnostik maligner Erkrankungen. I. Der Elektrophorese-Mobilitätstest in der Diagnostik des Bronchialkarzinoms. Dtsch Med Wochenschr 102: 419–422PubMedCrossRefGoogle Scholar
  33. Drysdale JW, Adelman TG, Arosio P (1977) Human isoferritin in normal and disease state. Semin Hematol 14: 71–85PubMedGoogle Scholar
  34. Dungern E von (1912) Serodiagnostik der Geschwülste mittels Komplementbindungsreaktion. Muench Med Wochenschr 59:65–67, 1093–1095, 2854–2856Google Scholar
  35. Eagan RT, Maurer LH, Forcier RJ, Tulloh M (1974) Small cell carcinoma of the lung, staging, paraneoplastic syndromes, treatment and survival. Cancer 33: 527–532PubMedCrossRefGoogle Scholar
  36. Eimermacher H, Tinnefeld W, Pressler H, Schuster P, Beyer HK (1979) CEA und CEA-ähnliche Aktivitäten in Aszites und Pleuraergüssen. Klin Wochenschr 57: 575–580PubMedCrossRefGoogle Scholar
  37. Epenetos AA, Britton KE, Mather S, Granowska M, Nimmon CC, Hawkins LR, Britton KE, Shepherd J, Taylor-Papadimitriou J, Durbin H, Malpas JS, Bodmer WF (1982) Targeting of iodine- 123-labelled tumor-associated monoclonal antibodies for diagnosis og malignancy in serous effusions. Lancet 11:830–836, 999–1006Google Scholar
  38. Fisher GL, Spittler LE, McNeil KL, Rosenblatt LS (1981) Serum copper and zinc level in melanoma patients. Cancer 47: 1838–1844PubMedCrossRefGoogle Scholar
  39. Fishman WH, Inglis NR, Stolbach LL, Krant MJ (1968) A serum alkaline phosphatase isoenzyme of human neoplastic cell origine. Cancer Res 28: 150–154PubMedGoogle Scholar
  40. Freund E, Kaminer G (1910) Über die Beziehungen zwischen Tumorzellen und Blutserum. Wien Klin Wochenschr 23: 1221–1223Google Scholar
  41. Fritsche R, Mach JP (1975) Identification of a new oncofetal antigen associated with several types of human carcinomas. Nature 258: 734–737PubMedCrossRefGoogle Scholar
  42. Frost MJ, Rogers GT, Bagshawe KD (1975) Extraction and preliminary characterisation of a human bronchogenic carcinoma antigen. Br J Cancer 31: 379–386PubMedCrossRefGoogle Scholar
  43. Gaffar SA, Braatz JA, Kortright KH et al. (1979) Further studies on a human lung tumor-associated antigen; Comparation of antigens from different tumors. J Biol Chem 254: 2097–2102PubMedGoogle Scholar
  44. Gerwitz G, Yalow RS (1974) Ectopic ACTH production in carcinoma of the lung. J Clin Invest 53: 1022–1032CrossRefGoogle Scholar
  45. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR, Estes N, Desimone P, Rayburn P (1978) Use of radiolabeled antibodies to CEA for the detection and localisation of diverse cancers by external photoscanning. N Engl J Med 299: 1384–1388CrossRefGoogle Scholar
  46. Goldenberg DM, Kim E, DeLand FH, Bennett S, Primus FJ (1980) Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 40: 2984–2992PubMedGoogle Scholar
  47. Griffith J (1982) Creatinine kinase isoenzyme 1 in the detection of lung neoplasia. Cancer Detect Prev 5: 257Google Scholar
  48. Gropp C, Havemann K, Lehmann FG (1978) CEA and ferritin in patients with lung cancer before and during therapy. Cancer 42: 2802–2808PubMedCrossRefGoogle Scholar
  49. Gropp C, Havemann K, Schärfe T (1979) Zirkulierende Immunkomplexe beim Bronchialkarzinom; Beziehungen zum Ausbreitungsstadium der Erkrankung und zur Therapie. Klin Wochenschr 57: 401–411PubMedCrossRefGoogle Scholar
  50. Gropp C, Havemann K, Scheuer A (1980) Ectopic hormones in lung cancer patients at diagnosis and during therapy. Cancer 46: 347–354PubMedCrossRefGoogle Scholar
  51. Gropp C, Havemann K, Kalbfleisch H, Luster W, Sosstmann H (1982) Antidiuretisches Hormon bei Patienten mit Bronchialkarzinom. Dtsch Med Wochenschr 107: 974–977PubMedCrossRefGoogle Scholar
  52. Hällgren R, Arrendal H, Hiesche K, Lundquist G, Nöu E, Zetterström O (1980) Elevated serum immunoglobulin E in bronchial carcinoma; Its relation to histology and prognosis of cancer. J Allergy Clin Immunol 67: 398–406Google Scholar
  53. Halliday WJ, Maluish A, Isbister WH (1974) Defection of cell mediated immunity and serum blocking factors in cancer patients by the leucocyte adherence inhibition test. Br J Cancer 29: 31–35PubMedCrossRefGoogle Scholar
  54. Hansen M, Hansen HH, Hirsch FR, Arends J, Christensen JD, Christensen JM, Hummer L, Kühl C (1980 a) Hormonal polypeptide and amino metabolites in small cell carcinoma of the lung with special reference to stage and subtypes. Cancer 45: 1432–1437Google Scholar
  55. Hansen M, Hammer M, Hummer L (1980 b) ACTH, ADH and calcitonine concentrations as markers of response and relapse in small cell carcinoma of the lung. Cancer 45: 2062–2067Google Scholar
  56. Harris CC, Primack A, Cohen MH (1974) Elevated alpha-1-antitrypsin serum levels in lung cancer patients. Cancer 34: 280–281PubMedCrossRefGoogle Scholar
  57. Herbermann RB (1974) Delayed hypersensitivity skin reactions to antigens of human tumors. Cancer 34: 1469–1473CrossRefGoogle Scholar
  58. Hoffer P (1980) Gallium: Mechanisms. J Nucl Med 21: 282–285PubMedGoogle Scholar
  59. Hughes NR (1971) Serum concentration of gamma-G, gamma-A and gamma-M immunoglobulins in patients with carcinoma, melanoma and sarcoma. J Natl Cancer Inst 46: 1015–1027PubMedGoogle Scholar
  60. Kahn H, Potthof P (1923) Die Hemmung der Natriumoleathämolyse durch das Serum bei verschiedenen Krankheiten, insbesondere bei malignen Tumoren. Z Exp Med 29: 169–189CrossRefGoogle Scholar
  61. Kaminer G (1933) Die diagnostische Verwendbarkeit der Freund-Kaminer Impfreaktion zur Erkennung von Karzinomen. Wien Klin Wochenschr 46: 1576–1577Google Scholar
  62. Kato Y, Fergusan TB, Bennet DE, Burford TH (1969) Oat cell carcinoma of the lung; A review of 138 cases. Cancer 23: 517–524PubMedCrossRefGoogle Scholar
  63. Kelly BS, Levy JG (1979) Detection of tumor-associated antigen in human bronchogenic carcinoma by the enzyme-linked immunosorbent assay (ELISA). Br J Cancer 41: 388–398CrossRefGoogle Scholar
  64. Kempken K, Langhammer H, Hör G, Pabst HW (1978) Szintigraphische und klinisch-experimentelle Untersuchungen mit 67-Gallium an 142 Bronchialkarzinompatienten. Nuklearmedizin 17: 47–52PubMedGoogle Scholar
  65. Kempner D, Jay MR, Stevens RH (1979) Human lung tumor-associated antigen of 32 000 D MG.V J Natl Cancer Inst 63: 1121–1127Google Scholar
  66. Kersten W (1983) Tumorbehandlung: Erfolgskontrolle durch Polyaminanalyse? Dtsch Med Wochenschr 108: 243–245PubMedCrossRefGoogle Scholar
  67. Kleist S v (1979) Antigens cross reacting with CEA. Evaluation of their interrelationship and clinical role. In: Lehmann FG (ed) Carcino-embryonic antigens, vol I. Biomedical Press, Elsevier, North Holland New York, p 35–39Google Scholar
  68. Klockars M, Lindgren J, Petterson T, Hellström PE, Norhagen A (1980) Carcinoembryonic antigen in pleural effusions; A diagnostic and prognostic indicator. Eur J Cancer 16: 1149–1152PubMedCrossRefGoogle Scholar
  69. Lamerz R, Fateh-Moghadam A (1975) Carcinofetale Antigene. Klin Wochenschr 53:147–170, 193–205, 403 - 418CrossRefGoogle Scholar
  70. Langhammer H, Glaubitt G, Grebe SF (1972) 67-Gallium for tumor scanning. J Nucl Med 13: 25–30Google Scholar
  71. Lehmann FG (1980) Preparation of monospecific antisera for immunoassay of human placental (Regan) and intestinal alkaline phosphatase. J Immunol Methods 36: 137–148PubMedCrossRefGoogle Scholar
  72. Lockich J J (1982 a) Frequency and clinical biology of the ectopic hormone syndromes of small cell carcinoma. Cancer 50:2111–2114Google Scholar
  73. Lockich JJ (1982b) Plasma CEA levels in small cell lung cancer; Correlation with stage, distribution of metastases and survival. Cancer 50: 2154–2156CrossRefGoogle Scholar
  74. Messmer G (1968) Der Plasmaeisenumsatz vor und nach zytostatischer Therapie und seine Bedeutung als Indikator der Tumoraktivität. Klin Wochenschr 46: 1278–1281PubMedCrossRefGoogle Scholar
  75. Milano G, Cooper EH, Coligher JC, Giles GR, Neville AM (1978) Serumprealbumin, retinol binding protein, transferrin and albumin levels in patients with large bowel cancer. J Natl Cancer Inst 61: 678–692Google Scholar
  76. Milano G, Viguier E, Cassuto JP, Schneider M, Namer M, Boublil JL, Lesbats G, Cambon P, Krebs BF, Laianne CM (1980) Polyamides et affections malignes. Pathol Biol (Paris) 28: 328–334Google Scholar
  77. Mohr JA, Rhoades ER, Coalson RE, Coalson JJ (1974) Alveolar cell carcinoma like antigen and antibodies in patients with alveolar cell carcinoma and other cancers. Cancer Res 34: 1904–1907PubMedGoogle Scholar
  78. Mordasini C, Riesen W, Morell A (1982) Serum ß-1-microglobulin and other tumor associated antigen in patients with bronchogenic carcinoma. Lung 160: 186–194CrossRefGoogle Scholar
  79. Muhrer KH, Filler D, Schwemmle K, Gierhake FW (1982 a) Klinische Relevanz zellulärer Immunität beim Bronchialkarzinom. Prax Pneumol 36: 335–339Google Scholar
  80. Muhrer KH, Filler D, Pasurka B (1982b) Immunologische Primärtumorlokalisation. Chirurg 53: 112–116PubMedGoogle Scholar
  81. Nash DR, McLarty JW, Fortson NG (1980) Pretreatment, prediagnosis immunoglobulin and alpha-1- antitrypsin levels in patients with bronchial carcinoma. J Natl Cancer Inst 64: 721–724PubMedGoogle Scholar
  82. Nieweg OE, Beekhuis H, Piers DA, Sluiter HJ, Van der Wal AM, Woldring MG (1983) 57-Co- Bleomycine and 67-Ga-citrate in detecting and staging lung cancer. Thorax 38: 16–21Google Scholar
  83. Nilsson K, Evrin PE, Welsh KI (1974) Production of microglobulin by normal and malignant human cell lines and peripheral lymphocytes. Transplant Rev 21: 53–84PubMedGoogle Scholar
  84. Nydegger KE, Butler RE (1972) Serum lipoprotein levels in patients with cancer. Cancer Res 32: 1756–1760PubMedGoogle Scholar
  85. Odell WD, Wolfsen AF, Yoshimoto Y, et al. (1977) Ectopic peptide synthesis; An universal concomitant of neoplasia. Clin Res 25: 524AGoogle Scholar
  86. Parson RG, Todd HD, Kowal R (1979 a) Isolation and identification of a human serum fibronectin like protein elevated during malignant diseases. Cancer Res 3: 4341–4345Google Scholar
  87. Parson RG, Aldenderfer PH, Kowal R (1979 b) Detection of a human seram-DNA-binding protein associated with malignant disease. J Natl Cancer Inst 63: 43–48Google Scholar
  88. Plesnicar S, Rudolf Z (1979) Serum immunoglobulin levels and survival rates in bronchogenic carcinoma patients. Neoplasma 26: 721–728PubMedGoogle Scholar
  89. Pressman D (1949) The zone of activity of antibodies as determinated by the use of radioactive tracers. Ann N Y Acad Sei 11: 203–206Google Scholar
  90. Rasker JJ, Poll van de MAPC, Beekhuis H, Woldring MG, Nieweg HO (1975) Some experience with 57-Co-labelled bleomycine as an tumor-seeking agent. J Nucl Med 16: 1058–1069Google Scholar
  91. Rassam JW, Anderson G (1975) Incidence of paramalignant disorders in bronchogenic carcinoma. Thorax 30: 86–9071PubMedCrossRefGoogle Scholar
  92. Ratcliffe JG, Podmore J, Stack HR, Spilg WGS, Gropp C (1972) Circulating ACTH and related peptides in lung cancer. Br J Cancer 45: 230–236CrossRefGoogle Scholar
  93. Rees CH, Ratcliffe JG (1974) Ectopic hormone production by non-endocrine tumours. Clin Endocrinol (Oxf) 3: 263–299CrossRefGoogle Scholar
  94. Rogers GT, Rawlins GA, Bagshawe KD (1981) Somatic cell hybrides producing antibodies against CEA. Br J Cancer 43: 1–4PubMedCrossRefGoogle Scholar
  95. Rostenberg I, Rico R, Penaloza R (1979) Gc-globulin and prealbumin serum levels in patients with cancer and inflammatory diseases and in asymptomatic smokers. J Natl Cancer Inst 62: 299–300PubMedGoogle Scholar
  96. Schick E, Frey HO, Holm E (1983) Bedeutung standardisierter CEA-Konzentrationen im Bronchialsekret mittels Xyloseverdünnungsmethode in der Diagnostik der Bronchialneoplasmen. Verh Dtsch Ges Inn Med 89: 1016–1021Google Scholar
  97. Schlegel G, Lüthgens M (1980) Klinische Bedeutung der tumorassozierten Immunglobuline dargestellt am Beispiel des IgE. Tumor Diagnostik 1: 24–30Google Scholar
  98. Schlegel G, Lüthgens M, Eklund G, Björklund B (1981) Correlation between activity in breast cancer and CEA, TPA and eighteen common laboratory procedures and the improvement by the combined use of CEA and TPA. Tumor Diagnostik 2: 6–11Google Scholar
  99. Schlipköter HW, Idel H, Barsoum AL, Vollmer UD (1973) Tumorcharakteristische Antigene im Bronchialkarzinom. Zbl Bakt Hyg I Abt B 158: 109–113Google Scholar
  100. Schryver-Kekcskemeti K De, Kariakos M, Bell CE, Seetharam S (1979) Pulmonary oat cell carcinomas; Expression of plasma membrane antigen correlated with presence of cytoplasmatic neurosecretory granules. Lab Invest 41: 432–436Google Scholar
  101. Schütt KH, Hoffmeister H (1971) Continous polyamid electrophoresis II. The diagnosis of malignant and inflammatory lung condition. Z Klin Chem 9:201–Google Scholar
  102. Sega E, Citro G, Natali PG (1979) Partial characterisation of a fetal lung antigen associated with human bronchogenic carcinoma. J Natl Cancer Inst 62: 1125–1130PubMedGoogle Scholar
  103. Sorensen GD, Pettengill OS, Brinck-Johnsen T, Cate CC, Maurer LH (1981) Hormone production by cultures of small cell carcinoma of the lung. Cancer 47: 1289–1296CrossRefGoogle Scholar
  104. Springer GF, Desai PR, Fry WA, Tegtmeyer H, Scanion EF (1982) T-Antigen and anti-T-antibodies are sensitive and specific in the detection of some categories of human carcinoma. Cancer Detect Prev 5:238 AGoogle Scholar
  105. Staab HJ, Anderer FA (1982) Growth of human colonic adenocarcinoma and development of secreted CEA in athymic mice I. A straight correlation of tumor size and mass with secreted CEA concentration during logarhythmic growth. Br J Cancer 46: 841–847PubMedCrossRefGoogle Scholar
  106. Takahashi A, Yachi A, Anzai T, Wada T (1967) Presence of an unique serum protein in sera abtained from patients with neoplastic diseases and in embryonic and neonatal sera. Clin Chim Acta 17: 5–13PubMedCrossRefGoogle Scholar
  107. Tautz C, Schneider W, Laier E, Brügmann G (1978) Der Elektrophorese-Mobilitäts(EM)-Test. Untersuchungsmethode zur Unterscheidung von malignen und nicht-malignen Tumoren. Klin Wo- chenschr 56: 175–185CrossRefGoogle Scholar
  108. Torstensson S, Thoren M, Hall K (1980) Plasma ACTH in patients with bronchogenic carcinoma. Acta Med Scand 207: 353–359PubMedCrossRefGoogle Scholar
  109. Twinning SS, Brecher AS (1977) Identification of alpha-1-acid-glycoprotein, alpha-2-macroglobulin and antithrombin III as components of normal and malignant human tissue. Clin Chim Acta 75: 143–148CrossRefGoogle Scholar
  110. Veltry RW, Mengoli HF, Maxim PF, Westfall S, Gopo JM, Huang CW, Sprinkle PM (1977) Isolation and identification of human lung tumor-associated antigens. Cancer Res 37: 1313–1322Google Scholar
  111. Vincent RG, Chu TM, Lan WW (1978) CEA as a monitoring of successful surgical resection in 130 patients with carcinoma of the lung. J Thorac Cardiovasc Surg 75: 734–739PubMedGoogle Scholar
  112. Vincent RG, Chu FM, Lane WW (1979) Value of CEA in patients with carcinoma of the lung. Cancer 44: 685–691PubMedCrossRefGoogle Scholar
  113. Viza D, Couvier M, Phillips J, Boucheix CL, Guerin RA (1975) Solubilisation of an antigen associated with certain bronchial tumors. Eur J Cancer 11: 765PubMedCrossRefGoogle Scholar
  114. Waalkes TP, Abeloff MD, Woo KB, Ettinger DS, Ruddo RS, Aldenderfer PH (1980) Carcinoem- bryonic antigen for monitoring patients with small cell carcinoma of the lung during treatment. Cancer Res 40: 4420–4427PubMedGoogle Scholar
  115. Wada T, Anzai T, Sato K (1966) Immunochemical approaches to the detection of carcinoma of the lung and the stomach. Tumor Res 1: 217–259Google Scholar
  116. Wintzer G, Koch O, Uhlenbruck G (1980) Die Bedeutung von C-l-Inaktivator, alpha-1 - An tichymotrypsin und Inter-alpha-Trypsin in der Diagnostik und Nachsorge maligner Tumoren. Lab Med 4: 134–138Google Scholar
  117. Wolf A, Micksche M, Bauer H (1981) An improved antigenic marker of human lung carcinomas and its use in radioimmunoassay. Br J Cancer 45: 261–267Google Scholar
  118. Wolfsen A, Odell WD (1979) Pro-ACTH; Early diagnosis of lung cancer. Am J Med 66: 765–772PubMedCrossRefGoogle Scholar
  119. Woods JC, Springs AI, Harris H, McGee JO (1982) An new marker for human cancer cells. Lancet 11: 512–514CrossRefGoogle Scholar
  120. Yachi A, Matsura Y, Carpenter CM, Hyde L (1968) Immunochemical studies on human lung cancer antigens soluble in 50% saturated ammonium sulphate. J Natl Cancer Inst 40: 663–683PubMedGoogle Scholar
  121. Yasunami R, Hashimoto Z, Ogura T, Hirao F, Yamamura Y (1981) Primary lung cancer producing alpha-1-fetoprotein; A case report. Cancer 47: 926–929PubMedCrossRefGoogle Scholar
  122. Zardi L, Carnemolla B, Cagnasso D, Santi L (1980) Alpha-2-macroglobulin in normal and malignant human cells. Eur J Cancer 16: 35–32PubMedCrossRefGoogle Scholar
  123. Ziegenhagen G, Drahovsky D (1983) Klinische Bedeutung des C-reaktiven Proteins. Med Klin 78: 21–24Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • U. Dold

There are no affiliations available

Personalised recommendations